Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | Chief Commercial Officer | June 12, 2026 | June 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date June 12, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,176 |
Reported balance
After 2026-06-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-12 · Exercise / conversion · Acquired 25,000 · Balance 37,176 F1: Includes 1,861 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 12,176 |
Reported balance
After 2026-06-12 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-12 · Sale · Disposed 25,000 · Balance 12,176 F2: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2032-05-23 | Direct | 519,588 |
Reported balance
After 2026-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-12 · Exercise / conversion · Disposed 25,000 · Balance 519,588 F3: Immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,861 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2025.
F2: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.
F3: Immediately exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 13, 2026 00:06 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001951287-26-000004 · form4-06132026_120610.xml · derivative · entry 3 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 519,588 Underlying: Common Stock · 25,000 shares Expires 2032-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| June 12, 2026 Filed Jun 13, 2026 00:06 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 25,000 | $10.00 | $250,000.00 |
DisclosureSEC source: 0001951287-26-000004 · form4-06132026_120610.xml · nonDerivative · entry 2 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,176 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. Read SEC document |
| June 12, 2026 Filed Jun 13, 2026 00:06 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 25,000 | $1.50 | $37,500.00 |
DisclosureSEC source: 0001951287-26-000004 · form4-06132026_120610.xml · nonDerivative · entry 1 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,861 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2025. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:26 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 240,000 | $0.00 Strike: $11.49 | $0.00 |
DisclosureSEC source: 0001951287-26-000002 · form4-01052026_090126.xml · derivative · entry 1 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:21 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-25-019321 · form4-07032025_080720.xml · derivative · entry 3 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 544,588 Underlying: Common Stock · 15,000 shares Expires 2032-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:21 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 15,000 | $16.99 | $254,860.50 |
DisclosureSEC source: 0001415889-25-019321 · form4-07032025_080720.xml · nonDerivative · entry 2 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,315 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024. F3 · price: The weighted average sale price for the transaction reported was $16.9907, and the range of prices were between $16.71 and $17.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:21 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 15,000 | $1.50 | $22,500.00 |
DisclosureSEC source: 0001415889-25-019321 · form4-07032025_080720.xml · nonDerivative · entry 1 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,619 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 22:38 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-25-017901 · form4-06202025_100641.xml · derivative · entry 3 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 559,588 Underlying: Common Stock · 15,000 shares Expires 2032-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 22:38 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 15,000 | $16.00 | $240,000.00 |
DisclosureSEC source: 0001415889-25-017901 · form4-06202025_100641.xml · nonDerivative · entry 2 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,696 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 22:38 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 15,000 | $1.50 | $22,500.00 |
DisclosureSEC source: 0001415889-25-017901 · form4-06202025_100641.xml · nonDerivative · entry 1 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 22:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-25-008796 · form4-03212025_060301.xml · derivative · entry 3 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 574,588 Underlying: Common Stock · 10,000 shares Expires 2032-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 22:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 10,000 | $14.00 | $140,000.00 |
DisclosureSEC source: 0001415889-25-008796 · form4-03212025_060301.xml · nonDerivative · entry 2 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,696 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 22:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 10,000 | $1.50 | $15,000.00 |
DisclosureSEC source: 0001415889-25-008796 · form4-03212025_060301.xml · nonDerivative · entry 1 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,003 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 152,300 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001415889-25-000459 · form4-01032025_040122.xml · derivative · entry 1 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,300 Underlying: Common Stock · 152,300 shares Expires 2035-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025. Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,283 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-24-028349 · form4-12042024_091201.xml · derivative · entry 6 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 584,588 Underlying: Common Stock · 6,283 shares Expires 2032-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 6,283 | $14.00 | $87,962.00 |
DisclosureSEC source: 0001415889-24-028349 · form4-12042024_091201.xml · nonDerivative · entry 4 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,693 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024. Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 6,283 | $1.50 | $9,424.50 |
DisclosureSEC source: 0001415889-24-028349 · form4-12042024_091201.xml · nonDerivative · entry 3 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,717 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-24-028349 · form4-12042024_091201.xml · derivative · entry 5 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 590,871 Underlying: Common Stock · 3,717 shares Expires 2032-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 3,717 | $14.11 | $52,461.37 |
DisclosureSEC source: 0001415889-24-028349 · form4-12042024_091201.xml · nonDerivative · entry 2 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,693 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024. F2 · price: The weighted average sale price for the transaction reported was $14.1139, and the range of prices were between $14.00 and $14.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 3,717 | $1.50 | $5,575.50 |
DisclosureSEC source: 0001415889-24-028349 · form4-12042024_091201.xml · nonDerivative · entry 1 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-24-023712 · form4-09192024_080927.xml · derivative · entry 3 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 594,588 Underlying: Common Stock · 10,000 shares Expires 2032-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 10,000 | $14.00 | $140,000.00 |
DisclosureSEC source: 0001415889-24-023712 · form4-09192024_080927.xml · nonDerivative · entry 2 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,693 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 10,000 | $1.50 | $15,000.00 |
DisclosureSEC source: 0001415889-24-023712 · form4-09192024_080927.xml · nonDerivative · entry 1 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:51 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-24-021885 · form4-08212024_100803.xml · derivative · entry 3 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 604,588 Underlying: Common Stock · 10,000 shares Expires 2032-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:51 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 10,000 | $14.00 | $140,000.00 |
DisclosureSEC source: 0001415889-24-021885 · form4-08212024_100803.xml · nonDerivative · entry 2 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,693 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:51 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 10,000 | $1.50 | $15,000.00 |
DisclosureSEC source: 0001415889-24-021885 · form4-08212024_100803.xml · nonDerivative · entry 1 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,984 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on June 30, 2023, 1,232 shares acquired under the ESPP on December 29, 2023 and 2,477 shares acquired under the ESPP on June 28, 2024. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:47 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $5.58 | $0.00 |
DisclosureSEC source: 0001209191-24-000818 · doc4.xml · derivative · entry 1 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001209191-23-001928 · doc4.xml · derivative · entry 1 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 614,588 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001209191-22-056446 · doc4.xml · derivative · entry 1 Karas Eric · CIK 0001951287 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 614,588 Underlying: Common Stock · 614,588 shares Expires 2032-05-24 F2 · price: Received in exchange for a stock option to acquire 520,000 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") with the exercise price of $1.77 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.